Navigation Links
Israel's Prestigious President's Conference to Feature Oramed Pharmaceuticals' Revolutionary Oral Insulin Capsule
Date:5/6/2008

Oramed is one of 60 Companies Selected to Participate at the "Facing

Tomorrow" Conference Marking the Country's 60th Birthday

JERUSALEM, Israel, May 6 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP), a developer of oral delivery systems, has been selected for the first annual Presidential conference, "Facing Tomorrow," as one of the 60 "enterprises of tomorrow" representing the future face of Israel. The monumental event is being held to mark the country's sixtieth birthday.

Additionally, Oramed was one of six companies chosen to be featured in a video presentation at the conference's opening event. The conference will be attended by global political and business leaders, including Israeli Prime Minister Ehud Olmert, President George W. Bush and Google founder Sergey Brin.

"The selection of Oramed as one of the companies to change the face of tomorrow is a great honor," said Nadav Kidron, CEO of Oramed Pharmaceuticals. "Being chosen for the conference illustrates the potential of our technology to make a significant difference for millions of diabetics around the world."

The conference will be held May 13-15 at the Jerusalem International Convention Center.

For more information on the conference, please visit the conference's website at: http://www.presidentconf.org.il/en/

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is an Israeli-based company focused on the development of oral delivery solutions based on proprietary technology. Oramed is currently developing an orally ingestible insulin capsule for the treatment of diabetes. The oral administration of insulin is more physiological than the current delivery method, mimicking the natural path of insulin throughout the body. The company is also pursuing the development of oral delivery solutions for drugs and vaccines presently delivered via injection.

For more information, please visit our website at: http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts:

Oramed Pharmaceuticals

Tara Horn

Cell: +972-54-33-44-318

Office: +972-2-566-0001

Email: tara@oramed.com

Media Contacts:

Ruder Finn Israel for Oramed

Matthew Krieger

Cell: +972-54-46-76-950

Office: +972-2-589-2003

Email: matthew@ruderfinn.co.il


'/>"/>
SOURCE Oramed Pharmaceticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Fraunhofer and Boston University Hosted Prestigious SME Tour
2. Prestigious Scientific Leaders Join InterWest Advisory Committee
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. Launch of New, Prestigious Infertility and Gynaecology Research GrAnt (FRIGGA)
5. Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service
6. Research by Case Western Reserve University, VA earns cover of prestigious science publication
7. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
8. Rutgers physicist earns prestigious Packard Foundation Science and Engineering Fellowship
9. Prestigious Bioethics Award for Scholar from Mexico
10. Physics professor lauded for NSF efforts with prestigious award
11. Physics professor lauded for NSF efforts with prestigious award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Opal Kelly, a leading producer ... using USB or PCI Express, announced the FOMD-ACV-A4, the company's first FPGA-on-Module for ... thin, SODIMM-style module that fits a standard 204-pin SODIMM socket for low-cost integrations ...
(Date:12/8/2016)... 2016 Oxford Gene Technology ... NGS panel range with the launch of the SureSeq myPanel™ ... of variants in familial hypercholesterolemia (FH). The panel delivers single ... a single small panel and allows customisation by ,mix and ... exons for LDLR , P C ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced today ... demand KbioBox developed a sophisticated “3 click” gene dditing off target analysis program ... new website, https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... the World Technology Awards. uBiome is one of just six company finalists in ... , In addition to uBiome, companies nominated as finalists in this year’s awards ...
Breaking Biology Technology:
(Date:12/6/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, and the ... five (5) year funding commitment by Securus to ... rehabilitation and reentry support to more inmates and ... 2004, the Prison Entrepreneurship Program (PEP) is an ...
(Date:12/2/2016)... The report "Biometric Vehicle Access ... (Iris Recognition System), Vehicle Type (Passenger Car, Battery ... 2021", published by MarketsandMarkets, the market is estimated ... is projected to grow to USD 854.8 Million ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... Poland , Nov. 30, 2016 Not many of us realize that ... aspects of recovery so we need to do it well. Inadequate sleep levels have ... high blood pressure, stroke, diabetes, and even cancer. Maybe now is the ... present that could help them to manage their sleep quality? ... ...
Breaking Biology News(10 mins):